Phanes Therapeutics Begins Dosing in Peluntamig Chemotherapy Study

Phanes Therapeutics, Inc., a biotech enterprise based in SAN DIEGO focusing on the innovative discovery and development of cancer therapies, has announced the commencement of a clinical trial involving its novel drug, peluntamig (PT217), in conjunction with chemotherapy. This significant milestone marks the first instance of a patient being administered peluntamig (PT217) within this study.

Peluntamig (PT217) is a pioneering bispecific antibody that mimics native IgG and targets DLL3 and CD47. This drug is engineered to treat patients affected by small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC), including forms such as neuroendocrine prostate cancer (NEPC). The United States Food and Drug Administration (FDA) has recognized the potential of peluntamig (PT217) by awarding it two orphan drug designations specifically for SCLC and NEC. Additionally, two Fast Track designations have been granted for its use in cases of extensive-stage small cell lung cancer (ES-SCLC) that have progressed following platinum chemotherapy, regardless of the use of a checkpoint inhibitor, and for metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

In the preceding year, Phanes entered a collaborative clinical supply agreement with Roche. This partnership is set to explore the effects of peluntamig (PT217) when combined with Roche’s anti-PD-L1 therapy, atezolizumab. The research is part of the multi-center, Phase I/II SKYBRIDGE trial, which is actively assessing the safety, tolerability, pharmacokinetics, and initial effectiveness of peluntamig (PT217) in patients suffering from advanced or treatment-resistant cancers that express DLL3. Parallel to this, a Phase I clinical trial is being carried out in China under the identifier CTR20242720.

Phanes Therapeutics is at the forefront of drug innovation in oncology, currently conducting three significant Phase I/II clinical trials. Among these are the MORNINGSTAR study featuring the advanced monoclonal antibody (mAb) program with mavrostobart (PT199), and the TWINPEAK study involving spevatamig (PT886), alongside the SKYBRIDGE study with peluntamig (PT217). Both spevatamig and peluntamig hold the distinction of being first-in-class bispecific antibodies that have obtained both orphan drug and Fast Track designations from the FDA.

The company’s robust pipeline is a result of its proprietary technology platforms, PACbody®, SPECpair®, and ATACCbody®. These platforms enable the development of innovative biologics designed to meet the significant unmet medical needs within oncology. Through these technological advancements, Phanes Therapeutics aims to make substantial contributions to cancer treatment.

Phanes Therapeutics continues to build upon its foundation of groundbreaking research and development, with the goal of providing effective treatment options for complex cancers. The ongoing clinical trials and collaborations underscore the company’s commitment to advancing cancer therapeutics and offering hope to patients suffering from these challenging diseases.